Amgen is testing their obesity drug candidate, MariTide, to see if they can wean patients toward lower doses over time. Very early data suggests that MariTide may provide longer-lasting weight loss than other popular obesity drugs and could potentially be taken less frequently. Amgen’s unique strategy is to transition patients to a less intensive dosing regimen and to see if they can maintain weight loss even after stopping the drug. The drug also has a unique mechanism and researchers are considering the possibility that it may be taken monthly for maintenance. Researchers are intrigued by the results and are looking into developing longer-lasting treatments for obesity.
Source link
Amgen wants Wegovy-like drug that can be tapered down
